Solid Biosciences' stock soars on early success in DMD gene therapy trial [Yahoo! Finance]
Solid Biosciences Inc. (SLDB)
Last solid biosciences inc. earnings: 8/14 07:25 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.solidbio.com/investor-relations
Company Research
Source: Yahoo! Finance
The US-based company's stock soared by 78.66% following the announcement, from a 14 February close of $4.03 to a high of $7.20 after the markets opened on 18 February. The company announced 90-day biopsy data from the Phase I/II Inspire DMD trial (NCT06138639) of its gene therapy candidate SGT-003. The first three patients, out of six, saw a 110% expression of microdystrophin, which can slow disease progression and potentially preserve muscle health. At the same time, the company reported improvements in multiple biomarkers used as indicators of muscle health and resilience, including a 78% increase in dystrophin-positive fibres. There was also a reduction in biomarkers associated with muscle stress and degeneration. It also a
Read more
Impact Snapshot
Event Time:
SLDB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLDB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLDB alerts
High impacting Solid Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SLDB
News
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Solid Biosciences Inc. (NASDAQ: SLDB) had its price target lowered by analysts at JPMorgan Chase & Co. from $12.00 to $11.00. They now have an "overweight" rating on the stock.MarketBeat
- Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceGlobeNewswire
- Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at HC Wainwright from $16.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $16.00 price target on the stock.MarketBeat
SLDB
Earnings
- 8/13/24 - Beat
SLDB
Sec Filings
- 3/17/25 - Form EFFECT
- 3/17/25 - Form EFFECT
- 3/13/25 - Form 4
- SLDB's page on the SEC website